A new study on the effectiveness of two intravenous treatments for trigeminal neuralgia

A retrospective study by IDIBELL and the Hospital Universitario de Bellvitge with 144 cases shows that intravenous treatment with lacosamide and phenytoin is effective and safe.

Leer más

Six runners complete the Zurich Marató de Barcelona and raise funds for ALS research

The runners resolved to collect 5,000 euros for ALS research at IDIBELL and the Bellvitge University Hospital. In exchange, they promised to complete the Marathon.

Leer más

Daniel Bravo Andreu Private Foundation awards a grant to Carles Diez to continue cutting-edge research in cardiology

The Daniel Bravo Andreu Private Foundation has awarded its grants for biomedical research stays at benchmark centres abroad to PhD candidate Carles Diez of Bellvitge University Hospital–Bellvitge Biomedical Research Institute (IDIBELL)

Leer más

The solidarity campaign “Elles contra l’ELA” kicks off

The “Elles contra ELA” solidarity campaign begins today with the aim of raising awareness about ALS and raising funds for research. This project is promoted by the research group on neurological and neurogenetic diseases of the Bellvitge Biomedical Research Institute (IDIBELL), with the support of the Catalan Foundation of ALS Miquel Valls, the sponsorship of …

The solidarity campaign “Elles contra l’ELA” kicks off Read More »

Leer más

A new system expands the gene-editing possibilities in animals

This new CRISPR-Cas9 tool can modify gene sites that were inaccessible until now, which bypasses the limited capabilities of gene editing and reinforce precision medicine.

Leer más

IDIBELL researchers present a new recombinant protein that reverses the proinflammatory state of cells in patients with lupus

The protein can slow down the proinflammatory activity of the immune cells and, therefore, stop their body attack.

Leer más

Begins the exchange program between IDIBELL and SZBL

It begins the selection of candidates to carry out a doctoral program in Regenerative Medicine between the SZBL and the IDIBELL. The program will run mainly at SZBL and will have a minimum six months stay at IDIBELL.

Leer más

SARS-CoV-2 vaccines are safe and effective in people with immunodeficiency

The analysis show that these vaccines are safe and able to generate immunity in three out of four patients with immune system defects from birth, and in almost all patients treated with immunosuppressants who were evaluated in the study.

Leer más

A clinical trial shows the safety and potential of an oncolytic virus against advanced pancreatic cancer

Preliminary results show that the virus is active, reaches the primary tumor and metastases, and triggers the immune system response. In addition, at recommended doses, it has no important adverse effects.

Leer más
Scroll to Top